ECT2L Activators
ECT2L activators encompass a diverse group of chemical compounds that modulate cellular pathways and processes to enhance the functional activity of Epithelial cell transforming 2 like (ECT2L), a guanine nucleotide exchange factor (GEF) involved in the regulation of the Rho family GTPases. These activators operate through various mechanisms of action, targeting a wide array of cellular components and signaling cascades. For instance, some activators work by influencing the levels of intracellular messengers such as cAMP, which can lead to the activation of protein kinases like PKA. These kinases are capable of phosphorylating substrates that interact with ECT2L, thereby modulating its activity. Other members of this chemical class such as MEK inhibitors (e.g., U0126 or PD98059) can affect the MAPK/ERK pathway, leading to cellular adjustments that influence ECT2L's role in the regulation of the cytoskeleton and cell cycle progression.
The cytoskeletal network, critical for maintaining cell shape and enabling various cellular movements, including division, is a major target of ECT2L activators. Compounds such as Rho GTPase inhibitors (e.g., NSC 23766) indirectly enhance ECT2L's GEF activity, crucial for cytoskeletal reorganization during cell division. In addition, inhibitors of signaling pathways like PI3K and CRAF (e.g., LY294002, Wortmannin, and ZM 336372) can also impact the functional activity of ECT2L by modulating processes that govern cell cycle progression. Furthermore, some ECT2L activators directly interact with components of the cytoskeleton; for example, stabilizers of microtubules and actin filaments enhance ECT2L's role in maintaining the integrity of these structures during the critical phases of cell division.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which plays a role in the regulation of cell proliferation and cytokinesis. PKC activation can enhance ECT2L activity by promoting the cytoskeletal reorganization necessary for these processes. | ||||||
Thrombin from human plasma | 9002-04-4 | sc-471713 | 100 U | $230.00 | ||
Thrombin activates protease-activated receptors (PARs) leading to RhoA signaling. ECT2L is a guanine nucleotide exchange factor (GEF) for Rho GTPases, thus thrombin can enhance ECT2L's GEF activity, promoting actin-myosin contraction during cytokinesis. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $119.00 $447.00 | 28 | |
Calpeptin is a calpain inhibitor which can stabilize the cytoskeleton by inhibiting degradation of cytoskeletal proteins. Stabilizing the cytoskeleton can enhance ECT2L activity by promoting its role in maintaining cellular structure during division. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium Chloride inhibits GSK-3, leading to Wnt pathway activation. Although Wnt proteins themselves are excluded, this downstream effect on the pathway stabilizes cytoskeletal elements, potentially enhancing ECT2L's role in cytokinesis. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $180.00 $299.00 | 59 | |
Jasplakinolide stabilizes actin filaments and promotes actin polymerization. By stabilizing the cytoskeleton, it can enhance ECT2L activity in regulating cytoskeletal dynamics during cell division. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, which by inhibiting the Rho/ROCK pathway can lead to cytoskeletal relaxation. This relaxation can enhance ECT2L's activity in the later stages of cytokinesis where cell separation occurs. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $71.00 $260.00 $485.00 $949.00 | ||
Blebbistatin is a myosin II inhibitor, which can prevent premature actin-myosin contraction. This can enhance ECT2L's role in regulating the timing of cytokinesis, ensuring proper cell division. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
ML-7 is a myosin light chain kinase (MLCK) inhibitor, which can modulate actin-myosin contraction. This modulation can enhance ECT2L function by fine-tuning the cytoskeletal changes during cytokinesis. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
NSC 23766 inhibits Rac1, a Rho GTPase. By modulating Rac1 activity, it can influence actin organization, which is crucial for ECT2L's role in cytokinesis, enhancing its functional activity in this process. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Paclitaxel stabilizes microtubules, which is essential for proper formation of the mitotic spindle and subsequent cytokinesis. This stabilization can enhance ECT2L activity by supporting its function in cell division. | ||||||